Evidence map›Paper›PMID 36339771›Full record

ArticleHeliyon2022

Evaluating the cost of collection, processing, and application of face masks in hot-mix asphalt (HMA) pavements.

Carol Massarra, Md Hasibul Hasan Rahat, George Wang, Husam Sadek

Abstract read
In one paragraph

Article in Heliyon, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Carol MassarraDepartment of Construction Management, East Carolina University, Greenville, NC 278585, USA.
Md Hasibul Hasan RahatDepartment of Civil and Environmental Engineering, Virginia Tech, Blacksburg, VA 24060, USA.
George WangDepartment of Construction Management, East Carolina University, Greenville, NC 278585, USA.
Husam SadekCivil & Pavement Engineer, SEERO Engineering LLC, Baton Rouge, LA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human activities significantly contribution to the yearly generated plastic wastes. Moreover, the enormous increase in face masks and face shields caused by the emergence of the COVID-19 pandemic has doubled the generated plastic wastes. Although there is an added benefit of using plastic waste in construction, the cost associated with their application, specifically the face mask, has not been addressed. This paper presents a simplified and rapid estimation of the cost associated with the collection, processing, and application of face masks in hot-mix asphalt (HMA) pavements. Two scenarios, mask modified asphalt pavement and conventional asphalt pavement, are considered. The total cost is based on market price and prices from waste management facilities and plastic processing companies. Life Cycle Cost Analysis (LCCA) is used to evaluate the long-term costs of mask modified asphalt pavement and conventional asphalt pavement. Results show that no significant difference in initial total cost between the two scenarios for pavement sections with lengths less than 500m and the number of lanes less than 6. The difference in total cost begins with lengths greater than 500 m for 5 and 6 Lanes. Despite the higher initial costs for the mask modified asphalt pavement, the LCCA shows that there is a 29% maintenance cost reduction over the 40 years life cycle of the asphalt pavement. The use of LCCA shows the benefit of the selection of the most cost-effective strategy and how the use of mask modified asphalt pavement over the conventional asphalt pavement can save money over the life cycle of the asphalt and improve rutting and stiffens.

Indexed as

Asphalt pavementsCost estimationCOVID-19Face masksLife cycle cost analysis (LCCA)

Identifiers

PMID36339771
PMCPMC9634361

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.